Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2012 by Seoul National University Hospital
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
First received: August 16, 2012
Last updated: August 20, 2012
Last verified: August 2012
In this study, the investigators examine whether aspirin or warfarin is useful for atrial fibrillation patients with chronic kidney disease.

Condition Intervention Phase
Atrial Fibrillation
Chronic Kidney Disease
Drug: warfarin
Drug: aspirin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Randomized Controlled Prospective Trial of Warfarin Versus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation and Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Thromboembolic event

Secondary Outcome Measures:
  • Major bleeding [ Designated as safety issue: Yes ]

Estimated Enrollment: 720
Study Start Date: September 2012
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: warfarin Drug: warfarin
Active Comparator: aspirin Drug: aspirin

Detailed Description:

randomised open labelled prospective study

We enroll patients with CHADS2 score 1 non-valvular AF with chronic kidney disease, and analyze all thromboembolic event or major bleeding event during follow-up period. Warfarin group take dose adjusted warfarin (target INR 2.0-3.0) and aspirin group take aspirin 100mg daly.

Thromboembolic events: Ischemic stroke or systemic arterial occlusion Major bleeding: gastrointestinal bleeding or intracranial bleeding (code 430, code 431, code 432 by ICD-9-CM codes)

-> Only the first event of each case will be used for the analysis


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • CHADS2 score 1 nonvalvular atrial fibrillation patients with chronic kidney disease

Exclusion Criteria:

  • HAS-BLED ≥30
  • History of syncope or seizure within 1 year
  • History of major bleeding event within 6 months
  • BP>180/100
  • Abnormal prothrombin time
  • Hypersensitivity of aspirin or warfarin
  • Folstein mini mental state examination score <26
  • Taking or had taken other anticoagulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01668901

Contact: Seil Oh, MD,PhD,FHRS 82-2-2072-2088 seil@snu.ac.kr
Contact: Myung-jin Cha, MD 82-10-9070-4090 chamj81@gmail.com

Korea, Republic of
Seoul Nationap University Hospital Not yet recruiting
Seoul, Korea, Republic of, 110-744
Contact: Seil Oh, MD, PhD,FHRS    82-2-2072-2088    seil@snu.ac.kr   
Sponsors and Collaborators
Seoul National University Hospital
  More Information

ClinicalTrials.gov Identifier: NCT01668901     History of Changes
Other Study ID Numbers: WASAK 
Study First Received: August 16, 2012
Last Updated: August 20, 2012
Health Authority: Korea: Food and Drug Administration

Keywords provided by Seoul National University Hospital:

Additional relevant MeSH terms:
Atrial Fibrillation
Kidney Diseases
Renal Insufficiency, Chronic
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Renal Insufficiency
Urologic Diseases
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents

ClinicalTrials.gov processed this record on May 26, 2016